Domestic approval progress tracking of Maribavir
Maribavir(Maribavir) is acytomegalovirus (CMV) treatment that is currently approved in several countries. In China, the approval progress of maribabavir is relatively fast, and it will be officially launched in December 2023. The drug has been included in China's medical insurance coverage, and patients can enjoy medical insurance reimbursement when purchasing it in hospitals or pharmacies. Maribavir is primarily used to treat patients with CMV infection who have failed to respond to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, especially those who develop CMV infection or disease after transplantation.

The launch of maribavivir, especially its approval in China, means that moreCMV infected patients will be able to receive effective treatment. Especially today, when anti-CMV drug resistance is becoming increasingly serious, maribabavir, as a new treatment option, brings more hope to patients. The addition of drugs has also improved the overall treatment level of domestic treatment of cytomegalovirus infection.
Domestic maribavir tablets (trade name: Yitaizhi) may be supplied in pharmacies of major hospitals after they are launched on the market. Patients can use this drug according to the doctor's advice. In addition, specific medical insurance reimbursement policies have been gradually implemented, and patients can enjoy financial support from medical insurance when using the drug. However, since the medical insurance policies in each region are different, you need to consult the local hospital or pharmacy for specific reimbursement conditions to understand whether you are eligible for reimbursement and the specific reimbursement ratio.
In general, the approval and marketing of maribavivir provides Chinese patients with new treatment options, especially in the treatment ofCMV infection. Its emergence has supplemented the shortcomings of traditional antiviral drugs. With the widespread application of maribavivir, it is expected to have a profound impact in the country, especially in reducing drug resistance and improving treatment success rates.
Reference materials:https://www.livtencity.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)